IVIG

EpiVax licenses Tregitope Technology to Maruho Co., Ltd. for development of Tregitope-based Therapies to Treat Autoimmune Condition

Retrieved on: 
Thursday, November 4, 2021
IVIG, Research, Biotechnology, Quality of life, Harvard Medical School, Vaccine, McGill University, Patient, Protein, Inflammation, Multimedia, Health, Active ingredient, Therapy, Pharmaceutical industry, Online shopping

PROVIDENCE, R.I., Nov. 4, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce an important commercial licensing agreement with Maruho Co., Ltd. ("Maruho") for EpiVax's patented Tregitope technology.

Key Points: 
  • PROVIDENCE, R.I., Nov. 4, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce an important commercial licensing agreement with Maruho Co., Ltd. ("Maruho") for EpiVax's patented Tregitope technology.
  • This marks an exciting step for Maruho and EpiVax towards continued expansion of the Tregitope program and translation to the clinic.
  • Epivax Inc, and Maruho Co., Ltd announce the signing of a commercial licensing agreement for Tregitope technology.
  • Maruho will be able to leverage their Tregitope license to enhance their in-house therapeutic development strategies for autoimmune conditions.

DGAP-News: Biotest AG: Biotest identifies a benefit with trimodulin in a relevant subgroup of hospitalised COVID-19 patients

Retrieved on: 
Monday, October 11, 2021
Patient, Inflammation, Multiple organ dysfunction syndrome, Immunoglobulin G, Adult, COVID-19, Antibody, IVIG, Immunoglobulin A, Mortality, Population, Research, Lung, Virus, Sepsis, Community-acquired pneumonia, Immune system, Death, SCAP, Severe acute respiratory syndrome coronavirus 2, Acute respiratory distress syndrome, Respiratory disease, Pneumonia, Disease, Bacteria, Immunoglobulin M, Tissue, Pharmaceutical industry, Vaccine

Biotest announced today that analysis of the complete data set of the ESsCOVID (Escape from severe COVID-19) trial revealed efficacy of trimodulin in a relevant subgroup of severely ill COVID-19 patients.

Key Points: 
  • Biotest announced today that analysis of the complete data set of the ESsCOVID (Escape from severe COVID-19) trial revealed efficacy of trimodulin in a relevant subgroup of severely ill COVID-19 patients.
  • However, the detailed post-hoc analyses of the complete data set revealed a notable benefit in a relevant subgroup of hospitalised patients with early systemic inflammation.
  • In this subgroup of 96 COVID-19 patients trimodulin was able to markedly reduce both worsening and mortality of patients compared to placebo treated patients.
  • Trimodulin is currently in clinical development for the treatment of patients with severe community-acquired pneumonia (sCAP) and for patients with severe COVID-19.

ADMA Biologics Announces Presentation on Respiratory Viral Infections at IDWeek 2021

Retrieved on: 
Friday, October 1, 2021
Infection, Protein, Influenza and Other Respiratory Viruses, Immunity, Feinberg School of Medicine, FDA, Immunodeficiency, Patient, University, Food and Drug Administration, Bacteria, Virus, Marketing, MS, United States, IVIG, Disease, Risk, Plasma, COVID-19, Organ transplantation, Johns Hopkins, Hepatitis B virus, USF, ADMA, Doctor of Philosophy, Nasdaq, Organ, PIDD, RSV, GLOBE, Vaccine

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 01, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA or the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced an exclusive educational event at IDWeek 2021 on respiratory viral infections, presented by nationally recognized clinical experts Dr. Michael Ison from Northwestern University and Dr. Jolan Walter from the University of South Florida and Johns Hopkins All Childrens Hospital.

Key Points: 
  • RAMSEY, N.J. and BOCA RATON, Fla., Oct. 01, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA or the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced an exclusive educational event at IDWeek 2021 on respiratory viral infections, presented by nationally recognized clinical experts Dr. Michael Ison from Northwestern University and Dr. Jolan Walter from the University of South Florida and Johns Hopkins All Childrens Hospital.
  • Two leading experts in the management of respiratory syncytial virus (RSV) and other respiratory viruses in immunocompromised patients will discuss todays key clinical challenges and emerging treatment strategies.
  • Information about ADMA Biologics and its products can be found on the Companys website at www.admabiologics.com.
  • ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida.

U.S. Intravenous Immunoglobulin Market Analysis Report 2021-2028: Robust Pipeline, Approval and Launch of Novel Products, and Increasing Government Initiatives - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 23, 2021
Health, Pharmaceutical, USD, National, Immunodeficiency, CAGR, Market share, Immunoglobulin therapy, FDA, Patient, Multifocal motor neuropathy, CSL Behring, IVIG, U.S. FDA, COVID-19, CIDP, NIH, Safety, Pharmaceutical industry

The U.S. intravenous immunoglobulin market size is expected to reach USD 10.24 billion by 2028.

Key Points: 
  • The U.S. intravenous immunoglobulin market size is expected to reach USD 10.24 billion by 2028.
  • Robust pipeline, approval and launch of novel products, and increasing government initiatives are expected to be the major factors driving the market.
  • Robust pipeline and increasing approvals and launches of novel products are anticipated to support the market growth over the forecast period.
  • Furthermore, increasing initiatives by various government organizations to boost the development of novel products are expected to support market growth over the forecast period.

Global Immunoglobulins Market Outlook & Forecast Report 2021-2026 with CSL Limited, Takeda Pharmaceutical Company Limited, and Grifols S.A Dominating the Industry - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 22, 2021
Biotechnology, Infectious Diseases, Health, Genetics, Pharmaceutical, Blood, Meningitis, USD, Sinusitis, Antibody, Degenerative disease, Octapharma, Inflammation, CAGR, Takeda Pharmaceutical Company, Population, Environment, IVIG, Growth, Awareness, Immunodeficiency, Primary immunodeficiency, Skin, Pneumonia, CSL Limited, Incidence, Industry, Plasma, Blood product, Healthcare, Pharmaceutical industry

The study considers the immunoglobulins market present scenario and its market dynamics for the period 2020-2026.

Key Points: 
  • The study considers the immunoglobulins market present scenario and its market dynamics for the period 2020-2026.
  • The market is led by primary immunodeficiency, which acquired 26.05% of the global immunoglobulins market in 2020.
  • The key players in the immunoglobulins industry are Takeda Pharmaceutical, CSL Limited, Grifols, S.A, Kendrion Biopharma, and Octapharma AG.
  • The global immunoglobulins industry is dominated by mainly three vendors, CSL Limited, Takeda Pharmaceutical Company Limited, and Grifols S.A.

DGAP-News: Biotest AG: Trimodulin does not reach the primary endpoint in the phase II trial in patients with severe COVID-19

Retrieved on: 
Friday, August 13, 2021
Tissue, Respiratory disease, Inflammation, II, Pneumonia, SCAP, Adult, CEO, Research, Sepsis, Disease, Community-acquired pneumonia, Patient, Multiple organ dysfunction syndrome, COVID-19, Immune system, Immunoglobulin M, Virus, Mortality, Lung, Severe acute respiratory syndrome coronavirus 2, Data, Immunoglobulin G, IVIG, Immunoglobulin A, Bacteria, Plasma, Pharmaceutical industry, Vaccine

Biotest announced today the outcome for its ESsCOVID (Escape from severe COVID-19) trial in patients with severe COVID-19.

Key Points: 
  • Biotest announced today the outcome for its ESsCOVID (Escape from severe COVID-19) trial in patients with severe COVID-19.
  • Topline data for the primary endpoint demonstrate no reduction in number of patients that either clinically worsened (deterioration rate) or died during the trial (mortality rate) compared to the placebo group.
  • A total of 166 adult patients with severe COVID-19 were enrolled in this multinational phase II clinical trial.
  • In contrast to the positive results from the earlier phase II trial with trimodulin in patients with severe community-acquired pneumonia no treatment benefit was achieved in the new indication COVID-19.

ADMA Biologics Reports Record Second Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments

Retrieved on: 
Wednesday, August 11, 2021
ADMA, PAI, COVID-19, Leadership, CGMP, Private Securities Litigation Reform Act, Hepatitis B virus, Safety, Bacteria, Environment, Immunodeficiency, Forward-looking statement, Wiskott–Aldrich syndrome, Blood, ID, Collection, HBsAg, Introduction, Plasma, Risk, Patient, San Jose BioCenter, FDA, Nasdaq, Blas, Mother, U.S. Securities and Exchange Commission, Marketing, Food, Infection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Liver cancer, Commercial, Hepatitis B, Biologics license application, Sex linkage, Company, Person, IVIG, Immunity, Antibody, Death, Way, BLA, Conference, GLOBE, 8-K, Cirrhosis, Virus, Lists of diseases, Physician, Hepatitis, Conditional sentence, Video game, Fine chemical, Pharmaceutical industry, Vaccine

RAMSEY, N.J. and BOCA RATON, Fla., Aug. 11, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported financial results for the three months ended June 30, 2021, its fiscal second quarter, and provided an overview of recent progress and accomplishments.

Key Points: 
  • ET
    RAMSEY, N.J. and BOCA RATON, Fla., Aug. 11, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA or the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported financial results for the three months ended June 30, 2021, its fiscal second quarter, and provided an overview of recent progress and accomplishments.
  • ADMA continues to achieve milestones and execute on its commercial and operational strategies as evidenced by the strong second quarter financial results and regulatory successes.
  • Select Second Quarter 2021 Achievements & Recent Corporate Developments:
    Continued Commercial Execution: Achieved second quarter 2021 total revenues of $17.8 million, compared to $7.8 million for the second quarter of 2020, reflecting a 129% increase.
  • ADMA will host a conference call today, August 11, 2021, at 4:30 p.m. Eastern Time, to discuss the fiscal second quarter 2021 financial results and recent corporate updates.